title: Clinician uptake of obesity-related drug information: a qualitative assessment using continuing medical education activities.
abstract: BACKGROUND
  Medications necessary for disease management can simultaneously contribute to weight gain, especially in children. Patients with preexisting obesity are more susceptible to medication-related weight gain. How equipped are primary care practitioners at identifying and potentially reducing medication-related weight gain? To inform this question germane to public health we sought to identify potential gaps in clinician knowledge related to metabolic adverse drug effects of weight gain.
  
  
  METHODS
  The study analyzed practitioner responses to the pre-activity questions of six continuing medical education (CME) activities from May 2009 through August 2010.
  
  
  RESULTS
  The 20,705 consecutive, self-selected respondents indicated varied levels of familiarity with adverse metabolic effects and psychiatric indications of atypical antipsychotics. Correct responses were lower than predicted for drug indications pertaining to autism (-17% predicted); drug effects on insulin resistance (-62% predicted); chronic disease risk in mental illness (-34% predicted); and drug safety research (-40% predicted). Pediatrician knowledge scores were similar to other primary care practitioners.
  
  
  CONCLUSIONS
  Clinicians' knowledge of medication-related weight gain may lead them to overestimate the benefits of a drug in relation to its metabolic risks. The knowledge base of pediatricians appears comparable to their counterparts in adult medicine, even though metabolic drug effects in children have only become prevalent recently.
authors.affiliation: Johns Hopkins Bloomberg School of Public Health, Center for Human Nutrition, 198 Prince George St, Annapolis, MD 21401, USA. kohlstadt@outlook.com
authors.forename: Ingrid
authors.initials: I
authors.lastname: Kohlstadt
authors.forename: Gerold
authors.initials: G
authors.lastname: Wharton
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects; D002784:Cholesterol / Q000097:blood; D002908:Chronic Disease; D004346:Drug Information Services; D004502:Education, Medical, Continuing; D005069:Evaluation Studies as Topic; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced / Q000188:drug therapy; D009765:Obesity / Q000139:chemically induced / Q000188:drug therapy*; D010820:Physicians; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D014280:Triglycerides; D002784:Cholesterol